Affymax & Hot Topic News: (NASDAQ: AFFY), (NASDAQ: HOTT)
New York, NY -- (ReleaseWire) -- 03/08/2013 --Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Affymax, Inc. (NASDAQ: AFFY) and certain of its officers. The class action filed in United States District Court, Central District of California, and docketed under C13-1025 SI, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Affymax between December 8, 2011 and February 22, 2013, both dates inclusive of (the "Class Period").
Affymax is a Palo Alto-based biopharmaceutical company whose primary drug offering is Omontys (peginesatide) Injection for the treatment of anemia in chronic kidney disease in adult patients on dialysis.
Find out if this is the moment investors have been waiting for before trading AFFY here: http://www.wallstreetreport.net/market-scan/?symbol=AFFY
Hot Topic Inc. (NASDAQ: HOTT) and Sycamore Partners announced that they have entered into a definitive agreement pursuant to which Sycamore Partners will acquire Hot Topic for $14.00 per share in cash, or a total of approximately $600 million. The agreement, which has been unanimously approved by Hot Topic’s Board of Directors, represents a premium of approximately 30% over Hot Topic’s closing stock price on March 6, 2013.
Lisa Harper, Chief Executive Officer and Chairman of the Board of Hot Topic, said, “We are pleased that this transaction will allow us to deliver positive results for our shareholders. In addition, we are very excited about the future growth for the company and know that Sycamore Partners will provide great resources and expertise to us as we operate as a private company.”
Get the free and full daily trend analysis report on HOTT here:
WallStreetReport.net issues momentum alerts on stocks that can provide gains to day traders. WallStreetReport.net provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. WallStreetReport.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetReport.net is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the WallStreetReport.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Report believes traders should have a chance at successfully trading Penny Stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.WallStreetReport.net
WallStreetReport.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetreport.Net website, for complete risks and disclosures.
BlueLys, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.
For full disclaimer visit: http://www.wallstreetreport.net/disclaimer-2/
WALL STREET REPORT
Media Relations Contact
View this press release online at: http://rwire.com/219483